Scholarlink

Background <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a global health concern, with projections indicating it may become the leading cause of liver transplantation. MASLD is an updated terminology for NAFLD (non-alcoholic fatty liver disease), is characterized by hepatic steatosis with concurrent at least one cardiometabolic risk factor, primarily influenced by dietary habits, in the absence of secondary causes such as alcoholism, Concurrently, the incidence of inflammatory bowel disease (IBD) is rising in the Arab world. Traditionally considered a wasting disease, recent studies suggest an increased prevalence of MASLD among IBD patients compared to the general population. This study aimed to determine the prevalence of MASLD in IBD patients and assess the contributing risk factors.</p> Study design and methodology <p>A cross-sectional analytical study was conducted across two centers, including 81 patients diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD), with no prior hepatic disease or alcohol intake. After obtaining informed consent, patients underwent: clinical assessment (history, examination), Laboratory investigations (lipid profile, liver enzymes) Fibro Scan with Controlled Attenuation Parameter (CAP score) to quantify liver steatosis. Patients were classified into two groups: IBD with steatosis group: CAP &gt; 217&#xa0;dB/m, IBD without steatosis group: CAP ≤ 217&#xa0;dB/m. Statistical analysis was performed to compare risk factors between groups.</p> Results <p>42.5% of IBD patients had liver steatosis, 23.7% had MASLD, in comparing risk factors in steatotic and non steatotic groups, they did not differ regarding their IBD phenotype, extension, presence or absence of extraintestinal manifestations, disease duration, disease activity, and type of treatment received. Regarding non-IBD risk factors, the steatosis group was older with higher body mass index, higher triglyceride, cholesterol, and glycated hemoglobin level.</p> Conclusion <p>Steatotic liver disease&#xa0;affects nearly less than half of IBD patients, primarily due to metabolic risk factors rather than IBD-specific characteristics. These findings highlight the importance of early metabolic screening in IBD patients to mitigate MASLD progression.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease patients: an Egyptian cross-sectional study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月16日

查看全文
  • Shimaa Y. kamel,
  • Mohamed Amin Sakr,
  • Waleed Hamed,
  • Hoda M. Farid,
  • Amr Alaa El-Din,
  • Ismail Anwar,
  • Hany Shehab,
  • Salma Omran,
  • Mirella Sherif,
  • Mohamed Negm,
  • Nouran M. Bahig Elmihi,
  • Dina Fathy

摘要

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a global health concern, with projections indicating it may become the leading cause of liver transplantation. MASLD is an updated terminology for NAFLD (non-alcoholic fatty liver disease), is characterized by hepatic steatosis with concurrent at least one cardiometabolic risk factor, primarily influenced by dietary habits, in the absence of secondary causes such as alcoholism, Concurrently, the incidence of inflammatory bowel disease (IBD) is rising in the Arab world. Traditionally considered a wasting disease, recent studies suggest an increased prevalence of MASLD among IBD patients compared to the general population. This study aimed to determine the prevalence of MASLD in IBD patients and assess the contributing risk factors.

Study design and methodology

A cross-sectional analytical study was conducted across two centers, including 81 patients diagnosed with ulcerative colitis (UC) or Crohn’s disease (CD), with no prior hepatic disease or alcohol intake. After obtaining informed consent, patients underwent: clinical assessment (history, examination), Laboratory investigations (lipid profile, liver enzymes) Fibro Scan with Controlled Attenuation Parameter (CAP score) to quantify liver steatosis. Patients were classified into two groups: IBD with steatosis group: CAP > 217 dB/m, IBD without steatosis group: CAP ≤ 217 dB/m. Statistical analysis was performed to compare risk factors between groups.

Results

42.5% of IBD patients had liver steatosis, 23.7% had MASLD, in comparing risk factors in steatotic and non steatotic groups, they did not differ regarding their IBD phenotype, extension, presence or absence of extraintestinal manifestations, disease duration, disease activity, and type of treatment received. Regarding non-IBD risk factors, the steatosis group was older with higher body mass index, higher triglyceride, cholesterol, and glycated hemoglobin level.

Conclusion

Steatotic liver disease affects nearly less than half of IBD patients, primarily due to metabolic risk factors rather than IBD-specific characteristics. These findings highlight the importance of early metabolic screening in IBD patients to mitigate MASLD progression.